LNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, Lantheus Holdings Inc (LNTH) does not present a compelling buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has mixed financial performance, and shows neutral technical indicators. Additionally, insider and hedge fund selling, along with no recent Congress trading data, further diminishes confidence in the stock's immediate upside potential.
The MACD histogram is negative (-0.574) and contracting, indicating weak momentum. RSI is neutral at 51.261, and moving averages are converging, showing no clear trend. The stock is trading near its pivot point (75.258) with resistance at 77.422 and support at 73.094, suggesting limited immediate price movement.
Analysts have raised price targets recently, with Jefferies projecting a target of $110 and others highlighting growth prospects in the PSMA PET market and upcoming product rollouts. The stock has a 6.44% chance of growth over the next month based on candlestick pattern analysis.
Hedge funds and insiders are selling significantly, with insider selling increasing by 5211.12% in the last month. Financial performance in Q4 2025 showed a sharp decline in net income (-558.76%) and EPS (-576.47%), despite a modest revenue increase (4.01%). No recent news or Congress trading data to support a positive sentiment.
In Q4 2025, revenue increased by 4.01% YoY to $406.79M. However, net income dropped by 558.76% YoY to $54.09M, and EPS fell by 576.47% YoY to 0.81. Gross margin also declined to 59.21%, down 6.83% YoY, indicating weakening profitability.
Analysts maintain a generally positive outlook with several Buy and Outperform ratings. Price targets range from $75 to $110, reflecting optimism about future growth driven by product rollouts and market expansion. However, one analyst downgraded the stock to Hold, citing limited short-term revenue contributions from radiotherapeutic assets.
